ACIBSEARCHEAN CHEMICAL IND LTD· Chemicals & PetrochemicalsHighNeutral
Announced Thu, 30 Jul, 2026 · 20:34 IST

Q1 FY27 results: Revenue up 13%, PAT falls 22% on margin pressure

Ebitda Margin CompressionResults View source PDFExplain this filing

ACI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.7%Reaction day
₹559.00
prior close
₹556.00
announcement price
After-mkt
timing
Nifty Microcap 250market+1.1%-6.8% vs market
Specialty Chemicals peers, median of 94sector+0.4%-6.1% vs sector

On the reaction day the stock moved 6.8 pts less than Nifty Microcap 250 and 6.1 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.4
10m
-0.8
15m
-1.7
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.7+1.1-6.8+0.4-6.1
Next day
-4.6+2.4-7.1+1.6-6.3
2d
-5.0+2.9-7.9+1.3-6.3
3d
-6.4+4.2-10.6+1.8-8.2
4d
-7.2+4.6-11.8+2.7-9.9
5d
-9.5+4.6-14.1+2.2-11.7
1w
-8.2+4.4-12.6+3.0-11.2
15d
-11.0+5.7-16.7+2.6-13.6
1m
-13.3+6.6-19.9+4.3-17.7
2m
-12.6+5.4-18.0+2.6-15.2
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 standalone revenue rose 13% YoY to Rs 31,593 lakhs, but PAT fell 22% to Rs 4,053 lakhs as other expenses and finance costs compressed EBITDA margins from 33% to 25%. Consolidated PAT dropped 24% to Rs 3,035 lakhs. Company invested Rs 17,000 lakhs into subsidiary Acume Chemicals. Step-down subsidiary Sicsem signed a fiscal support pact with India Semiconductor Mission for up to 75% capital support. Auditors gave an unmodified review.

Likely market impact

Topline growth is positive, but sharp PAT decline and margin compression may pressure the stock. Subsidiary investments and semiconductor foray offer future optionality.